E
NGM

Ergoteles’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Ergoteles’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-23,410
Closed -$95.5K – 1663
2023
Q1 		$95.5K Buy
+23,410
New +$108K ﹤0.01% 1106
2021
Q3 		– Sell
-31,200
Closed -$615K – 1787
2021
Q2 		$615K Buy
+31,200
New +$730K 0.01% 706

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Ergoteles's NGM Position: Q2 2023 in Review

Ergoteles sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2023, closing a stake of 23,410 shares — an estimated $95.5K sold.

Ergoteles first reported a position in NGM in Q2 2021 and held it in 2 quarters. The position peaked at $615K in Q2 2021. 106 funds tracked by Wall St. Rank hold NGM as of Q2 2023.

  • Ergoteles reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 23,410 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $95.5K.
  • Ergoteles first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Ergoteles's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $615K in Q2 2021.
  • 106 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.